Efficacy of Aprepitant (Emend) in Children Receiving Highly Emetogenic Chemotherapy
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Aprepitant (Primary) ; Dexamethasone; Dexamethasone; Ondansetron; Ondansetron
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 22 Feb 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 22 Feb 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 22 Feb 2019 Status changed from recruiting to active, no longer recruiting.